Abstract:Background: The transmembrane subunit of the HIV envelope protein, gp41 is a vulnerable target to inhibit HIV entry. There is one fusion inhibitor T20 (brand name: Fuzeon, generic name: enfuvirtide) available by prescription. However, it has several drawbacks such as a high level of development of drug resistance, a short-half life in vivo, rapid renal clearance, low oral bioavailability, and it is only used as a salvage therapy. Therefore, investigators have been studying a variety of different modalities to attempt to overcome these limitations. Methods: Comprehensive literature searches were performed on HIV gp41, inhibition mechanisms, and inhibitors. The latest structural information was collected, and multiple inhibition strategies targeting gp41 were reviewed. Results: Many of the recent advances in inhibitors were peptide-based. Several creative modification strategies have also been performed to improve inhibitory efficacy of peptides and to overcome the drawbacks of T20 treatment. Small compounds have also been an area of intense research. There is a wide variety in development from those identified by virtual screens targeting specific regions of the protein to natural products. Finally, broadly neutralizing antibodies have also been important area of research. The inaccessible nature of the target regions for antibodies is a challenge, however, extensive efforts to develop better neutralizing antibodies are ongoing. Conclusion: The fusogenic protein, gp41 has been extensively studied as a promising target to inhibit membrane fusion between the virus and target cells. At the same time, it is a challenging target because the vulnerable conformations of the protein are exposed only transiently. However, advances in biochemical, biophysical, structural, and immunological studies are coming together to move the field closer to an understanding of gp41 structure and function that will lead to the development of novel drugs and vaccines.

Molecular Mechanism Of The Entry Of Hiv-1 Into Cells And The Related Drug Research

Mechanism of human immunodeficiency virus type I entry into the target cells

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

The HIV Env-mediated fusion reaction

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

The Molecular Mechanism of Two Coreceptor Binding Site Antibodies X5 and 17b Neutralizing HIV-1: Insights from molecular dynamics simulation.

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine

The Structural and Functional Researches of HIV-1 Gp41 NC Six-Helix-bundle

Quantifying the Sensitivity of HIV-1 Viral Entry to Receptor and Coreceptor Expression

High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting Gp41: Theories and Techniques.

Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41

Clinical Development and Application of HIV Entry Inhibitors

Progress in Studies of Structure, Mechanism and Antagonists Interaction of GPCR Co-Receptors for HIV.

Progress in the structure and function of human immunodeficiency virus type 1 gp41

The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

Development Of Small-Molecule Hiv Entry Inhibitors Specifically Targeting Gp120 Or Gp41

Molecular Docking and Molecular Dynamics Simulation to Predict Inhibitors Against HIV Envelope 1 Protein

Resolving the Sites of HIV Entry: Dynamin Networks Hold the Key

The Molecular Mechanism of Enveloped Virus-Cell Membrane Fusion

Small-molecule Inhibitors of HIV-1 Entry Block Receptor-Induced Conformational Changes in the Viral Envelope Glycoproteins.

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors